Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study

O. Sitbon (Paris, France), K. Chin (Texas, United States of America), R. Channick (Massachusetts, United States of America), L. Di Scala (Allschwil, Switzerland), S. Gaine (Dublin, Ireland), H. Ghofrani (London, United Kingdom), I. Lang (Vienna, Austria), V. Mclaughlin (Michigan, United States of America), R. Preiss (Allschwil, Switzerland), L. Rubin (California, United States of America), G. Simonneau (Paris, France), V. Tapson (California, United States of America), N. Galiè (Bologna, Italy), M. Hoeper (Hannover, Germany)

Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Session: Risk stratification in treatment of pulmonary arterial hypertension
Session type: Oral Presentation
Number: 268
Disease area: Pulmonary vascular diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Sitbon (Paris, France), K. Chin (Texas, United States of America), R. Channick (Massachusetts, United States of America), L. Di Scala (Allschwil, Switzerland), S. Gaine (Dublin, Ireland), H. Ghofrani (London, United Kingdom), I. Lang (Vienna, Austria), V. Mclaughlin (Michigan, United States of America), R. Preiss (Allschwil, Switzerland), L. Rubin (California, United States of America), G. Simonneau (Paris, France), V. Tapson (California, United States of America), N. Galiè (Bologna, Italy), M. Hoeper (Hannover, Germany). Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study. 268

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: